SER Stock Overview
A biotechnology company, develops drugs to treat neurological diseases and pain.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Serina Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.87 |
52 Week High | US$19.93 |
52 Week Low | US$5.85 |
Beta | 0 |
11 Month Change | 1.04% |
3 Month Change | -15.77% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -53.80% |
Recent News & Updates
Recent updates
Shareholder Returns
SER | US Biotechs | US Market | |
---|---|---|---|
7D | -3.2% | -0.7% | -1.6% |
1Y | n/a | 19.8% | 30.8% |
Return vs Industry: Insufficient data to determine how SER performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how SER performed against the US Market.
Price Volatility
SER volatility | |
---|---|
SER Average Weekly Movement | 14.4% |
Biotechs Industry Average Movement | 9.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SER's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SER's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 10 | Steve Ledger | serinatherapeutics.com |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy.
Serina Therapeutics, Inc. Fundamentals Summary
SER fundamental statistics | |
---|---|
Market cap | US$61.02m |
Earnings (TTM) | -US$7.01m |
Revenue (TTM) | US$3.17m |
19.2x
P/S Ratio-8.7x
P/E RatioIs SER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SER income statement (TTM) | |
---|---|
Revenue | US$3.17m |
Cost of Revenue | US$4.21m |
Gross Profit | -US$1.04m |
Other Expenses | US$5.97m |
Earnings | -US$7.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.79 |
Gross Margin | -32.68% |
Net Profit Margin | -220.87% |
Debt/Equity Ratio | -67.9% |
How did SER perform over the long term?
See historical performance and comparison